^
    3years
    Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (clinicaltrials.gov)
    P2, N=25, Recruiting, Jason Robert Gotlib | Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Oct 2023 | Trial primary completion date: Apr 2021 --> Apr 2023
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2) • ETV6 (ETS Variant Transcription Factor 6) • PCM1 (Pericentriolar Material 1)
    |
    JAK2 mutation • JAK2 rearrangement
    |
    Jakafi (ruxolitinib)